TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure

Background: Tyrosine kinase inhibitors (TKI) in combination with programmed cell death-1 (PD-1) inhibitors become the potential treatment modality for patients undergoing unresectable hepatocellular carcinoma (uHCC) in the first-line setting. However, the efficacy and safety of this combination regi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Jin, Chen, Bowen, Song, Meiru, Zhang, Linzhi, Zhang, Xinfeng, Gao, Xiaoqiang, Li, Yinyin, Lu, Yinying, Zuo, Shi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782409/
https://www.ncbi.nlm.nih.gov/pubmed/36569315
http://dx.doi.org/10.3389/fphar.2022.1026337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782409/
https://www.ncbi.nlm.nih.gov/pubmed/36569315
http://dx.doi.org/10.3389/fphar.2022.1026337

Ejemplares similares